{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:55:01Z","timestamp":1789905301642,"version":"4.0.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0194494","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T14:07:59Z","timestamp":1522764479000},"page":"e0194494","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-0852","authenticated-orcid":true,"given":"Konstantins","family":"Logviss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dainis","family":"Krievins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santa","family":"Purvina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"ref1","first-page":"1","article-title":"Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products","volume":"L18","year":"2000","journal-title":"Off J Eur Communities"},{"key":"ref2","first-page":"7","article-title":"Council recommendation of 8 June 2009 on an action in the field of rare diseases","volume":"C151","year":"2009","journal-title":"Off J Eur Union"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13023-014-0195-4","article-title":"Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints","volume":"10","author":"ED Kakkis","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(08)60876-4","article-title":"Clinical trials of orphan medicines","volume":"371","author":"BM Buckley","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","article-title":"Clinical research for rare disease: opportunities, challenges, and solutions","volume":"96","author":"RC Griggs","year":"2009","journal-title":"Mol Genet Metab"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"g6802","DOI":"10.1136\/bmj.g6802","article-title":"Innovative research methods for studying treatments for rare diseases: methodological review","volume":"349","author":"JJ Gagne","year":"2014","journal-title":"BMJ"},{"issue":"26","key":"ref7","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1200\/JCO.2008.21.1961","article-title":"Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?","volume":"27","author":"EA Richey","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ana.21676","article-title":"Pivotal studies of orphan drugs approved for neurological diseases","volume":"66","author":"J Mitsumoto","year":"2009","journal-title":"Ann Neurol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2125.2009.03369.x","article-title":"Orphan drug development is not taking off","volume":"67","author":"R Joppi","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e007199","DOI":"10.1136\/bmjopen-2014-007199","article-title":"Effectiveness, safety and costs of orphan drugs: an evidence-based review","volume":"5","author":"IJ Onakpoya","year":"2015","journal-title":"BMJ Open"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-015-0349-z","article-title":"Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.","volume":"10","author":"J Winstone","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00228-012-1423-2","article-title":"Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU","volume":"69","author":"R Joppi","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1750-1172-8-164","article-title":"Clinical evidence for orphan medicinal products\u2013a cause for concern?","volume":"8","author":"E Picavet","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1750-1172-8-124","article-title":"Systematic review of available evidence on 11 high-priced inpatient orphan drugs","volume":"8","author":"TA Kanters","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2125.2010.03877.x","article-title":"Access to orphan drugs despite poor quality of clinical evidence","volume":"71","author":"AG Dupont","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13023-014-0170-0","article-title":"A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov","volume":"9","author":"SA Bell","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13023-016-0434-y","article-title":"Impact of orphan drugs on Latvian budget","volume":"11","author":"K Logviss","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"13\/14","key":"ref18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.drudis.2012.02.005","article-title":"Orphan drug development: an economically viable strategy for biopharma R&amp;D","volume":"17","author":"KN Meekings","year":"2012","journal-title":"Drug Discov Today"},{"issue":"22","key":"ref19","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1001\/jama.2011.769","article-title":"Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer","volume":"305","author":"AS Kesselheim","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/clpt.2012.87","article-title":"Raising orphans: how clinical development programs of drugs for rare and common diseases are different","volume":"92","author":"M Orfali","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13023-015-0262-5","article-title":"Pressure for drug development in lysosomal storage disorders\u2013a quantitative analysis thirty years beyond the US orphan drug act","volume":"10","author":"K Mechler","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"1\/2","key":"ref22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drudis.2010.11.006","article-title":"Characteristics of orphan drug applications that fail to achieve marketing approval in the USA","volume":"16","author":"HE Heemstra","year":"2011","journal-title":"Drug Discov Today"},{"key":"ref23","article-title":"Committee for Medicinal Products for Human Use (CHMP)","year":"2006"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-6-49","article-title":"The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases","volume":"6","author":"BE Miyamoto","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13023-014-0147-z","article-title":"Rare diseases and orphan drugs: Latvian story","volume":"9","author":"K Logviss","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref26","unstructured":"Choice of control group in clinical trials. ICH topic E10. European Medicines Agency (EMA). 2001. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002925.ppd\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002925.ppd<\/ext-link>."},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/medicina44080074","article-title":"Legal assessment of current situation on orphan patients in Lithuania","volume":"44","author":"I Spokiene","year":"2008","journal-title":"Medicina (Kaunas)"},{"key":"ref28","unstructured":"Tuberculosis surveillance and monitoring in Europe 2016. Surveillance report. European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe. 2016. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/ecdc-tuberculosis-surveillance-monitoring-Europe-2016.pdf\" xlink:type=\"simple\">http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/ecdc-tuberculosis-surveillance-monitoring-Europe-2016.pdf<\/ext-link>."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13023-017-0597-1","article-title":"Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov","volume":"12","author":"SW Hee","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13023-016-0402-6","article-title":"Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions","volume":"11","author":"S Unkel","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"ref31","first-page":"e66","article-title":"A new toolkit for conducting clinical trials in rare disorders","volume":"21","author":"L Abrahamyan","year":"2014","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/annonc\/mdu500","article-title":"Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency","volume":"26","author":"H Maeda","year":"2015","journal-title":"Ann Oncol"},{"key":"ref33","first-page":"34","article-title":"Directive 2001\/20\/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use","volume":"L121","year":"2001","journal-title":"Off J Eur Communities"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0194494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T20:48:57Z","timestamp":1570999737000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0194494"}},"subtitle":[],"editor":[{"given":"Gerd","family":"Rosenkranz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0194494","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]}}}